Within CLL, we developed a functional disease classification based on BCR, MEK, and mTOR signaling and demonstrate that the resulting groups are characterized by distinctive sensitivities to many drugs. This evidence concerns the gene MTOR and B-cell chronic lymphocytic leukemia.